Literature DB >> 2155862

Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis.

F Dallegri1, L Ottonello, A Ballestrero, F Bogliolo, F Ferrando, F Patrone.   

Abstract

The aim of the present study was to investigate the effects of 5-aminosalicyclic acid (5-ASA) on the cell injury mediated by activated neutrophils. We used a system constituted of neutrophils, triggered with phorbol myristate acetate, and 51Cr-labelled Daudi cells as targets. The results show that 5-ASA is capable of efficiently preventing neutrophil-mediated lysis. 5-ASA was up to 10-fold more effective than taurine, which acts as an hypochlorous acid scavenger. Moreover, 5-ASA was found to compete with taurine for the neutrophil derived hypochlorous acid. The results are consistent with the conclusion that 5-ASA is capable of limiting the neutrophil mediated cell damage by scavenging the generated hypochlorous acid. This may represent a potential mechanism for the therapeutic action of 5-ASA in ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155862      PMCID: PMC1378377          DOI: 10.1136/gut.31.2.184

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Accumulation of hypothiocyanite ion during peroxidase-catalyzed oxidation of thiocyanate ion.

Authors:  T M Aune; E L Thomas
Journal:  Eur J Biochem       Date:  1977-10-17

2.  A possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: interaction with oxygen free radicals.

Authors:  P Del Soldato; M Campieri; C Brignola; G Bazzocchi; P Gionchetti; G A Lanfranchi; M Tamba
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

3.  Inhibition of neutrophil cytolysin production by target cells.

Authors:  F Dallegri; F Patrone; A Ballestrero; G Frumento; C Sacchetti
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

4.  Down-regulation of K cell activity by neutrophils.

Authors:  F Dallegri; F Patrone; G Frumento; A Ballestrero; C Sacchetti
Journal:  Blood       Date:  1985-03       Impact factor: 22.113

5.  Electrolytes and whole body potassium in acute leukemia.

Authors:  B Lantz; B Carlmark; P Reizenstein
Journal:  Acta Med Scand       Date:  1979

6.  Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation.

Authors:  S J Weiss; R Klein; A Slivka; M Wei
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

7.  Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity.

Authors:  P A Craven; J Pfanstiel; R Saito; F R DeRubertis
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

8.  Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.

Authors:  O H Nielsen; K Bukhave; J Elmgreen; I Ahnfelt-Rønne
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

9.  The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects?

Authors:  O I Aruoma; M Wasil; B Halliwell; B M Hoey; J Butler
Journal:  Biochem Pharmacol       Date:  1987-11-01       Impact factor: 5.858

Review 10.  Pharmacological and biochemical actions of sulphasalazine.

Authors:  J R Hoult
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more
  21 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

2.  Direct evidence of oxidative damage in acute and chronic phases of experimental colitis in rats.

Authors:  C Loguercio; G D'Argenio; M Delle Cave; V Cosenza; N Della Valle; G Mazzacca; C del Vecchio Blanco
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

3.  Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease.

Authors:  B Sido; V Hack; A Hochlehnert; H Lipps; C Herfarth; W Dröge
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 4.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine.

Authors:  Diana Couto; Daniela Ribeiro; Marisa Freitas; Ana Gomes; José L F C Lima; Eduarda Fernandes
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

6.  Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.

Authors:  Zahra Davoudi; Nathan Peroutka-Bigus; Bryan Bellaire; Michael Wannemuehler; Terrence A Barrett; Balaji Narasimhan; Qun Wang
Journal:  J Biomed Mater Res A       Date:  2017-12-21       Impact factor: 4.396

7.  Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid.

Authors:  S M Greenfield; N A Punchard; R P Thompson
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

8.  Inflammatory bowel disease--a radical view.

Authors:  N J Simmonds; D S Rampton
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

9.  A stable nitroxide radical effectively decreases mucosal damage in experimental colitis.

Authors:  F Karmeli; R Eliakim; E Okon; A Samuni; D Rachmilewitz
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

Review 10.  Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.

Authors:  Roja Rahimi; Shekoufeh Nikfar; Ali Rezaie; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2008-08-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.